Livarol in the treatment of chronic vulvovaginal candidiasis
The article presents the results of the study of treatment of women with chronic vulvovaginal candidiasis by vaginal suppositories Livarol, which contain 400 mg of ketoconazole.
Treatment was carried out according to two schemes. The main group (I) consisted of 22 women with chronic vulvovaginal candidiasis, who were prescribed treatment during the clinical manifestations of the disease in the form of Livarol in vaginal suppositories overnight during 10 days, then for three menstrual cycles in the same dosage during 5 days behind 7–10 days before the onset of menstruation. The comparison group (II) included 10 women with the same pathology, who were prescribed treatment only during the clinical manifestations of the disease in the form of Livarol in vaginal suppositories overnight during 10 days in one course. All patients were comparable in age and reproductive function and were treated on an outpatient basis.
The efficacy of treatment was assessed based on the disappearance of clinical symptoms and complaints (itching, burning, pain, caseous vaginal discharge), the lack of positive laboratory tests for the presence of fungal and pathogenic flora after 3, 6, 12 days and 1–10 months from the start of treatment. Therapy in the first group, which in the first stage provided for the elimination of exacerbation of chronic candidiasis by 10-day appointment of vaginal suppositories with ketoconazole, and at the second stage – 3-fold antiretroviral treatment for 5 days through 1 month, was more effective (90.9%). A single course of local treatment of chronic vulvovaginal candidiasis by Livarol within 10 days is less effective (60.0%).
The advantages of local use of ketoconazole are the rapid arresting of vulvovaginal candidiasis, a high concentration of antimycotic on the mucosa, the minimum frequency of side effects, the rapid normalization of the vaginal biocenosis, and the elimination of the effects of exo- and endocervicitis due to not only antimycotic but also antimicrobial action.
Full Text:PDF (Русский)
Dolgo-Saburova, Y.V. Clinical and laboratory features of chronic recurrent candidiasis of genitalia in women. Thesis abstract for PhD degree. St. Petersburg (2006): 22 p.
Mirzabalayeva, A.K. Candidiasis of the genitals in women in the practice of obstetrician-gynecologist. Tutorial. St. Petersburg (2009): 52 p.
Prilepskaya, V.N., Bayramova, G.R. “Vulvovaginal candidiasis – modern ways of solving the problem.” The difficult patient 4.9 (2006): 1–4.
Bingham, J.S. “What to do with the patient with recurrent vulvovaginal candidiasis.” Sex Transm Inf 75 (1999): 7.
Jilek, P., et al. Factors associated with recurrent vulvovaginal candidiasis dietary intake, cloting, sexual activities, personal hygiene, antibiotic use and allergies. 3 Trends in Medical Mycology. Turin (2007): 99.
Stamm, W.E. “Evaluating Guidelines.” Clinical Infectious Diseases 44 (2007): 775–6.
GOST Style Citations
1. Долго-Сабурова, Ю.В. Клинико-лабораторные особенности хронического рецидивирующего кандидоза гениталий у женщин: автореф. дис. … к. мед. н. / Ю.В. Долго-Сабурова. – Санкт- Петербург. – 2006. – 22 с.
2. Мирзабалаева, А.К. Кандидоз гениталий у женщин в практике акушера-гинеколога / Учебное пособие. – Санкт-Петербург. – 2009. – 52 с.
3. Прилепская, В.Н. Вульвовагинальный кандидоз – современные пути решения проблемы / В.Н. Прилепская, Г.Р. Байрамова // Трудный пациент. – 2006. – Т. 4, № 9. – С. 1–4.
4. Bingham, J.S. “What to do with the patient with recurrent vulvovaginal candidiasis.” Sex Transm Inf 75 (1999): 7.
5. Jilek, P., et al. Factors associated with recurrent vulvovaginal candidiasis dietary intake, cloting, sexual activities, personal hygiene, antibiotic use and allergies. 3 Trends in Medical Mycology. Turin (2007): 99.
6. Stamm, W.E. “Evaluating Guidelines.” Clinical Infectious Diseases 44 (2007): 775–6.
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)